
Elvina Almuradova/LinkedIn
May 18, 2025, 03:37
Elvina Almuradova: Are we nearing a Paradigm Shift in early ER+/HER2- Breast Cancer?
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO, shared a post on X:
“Are we nearing a paradigm shift in early ER+/HER2- breast cancer?
ESMOBreast25 data from ADAPTcycle & OPTIMA suggest similar outcomes with Ribociclib or MPA-guided ET vs chemo in select patients.
Clinical and genomic risk stratification is key.”
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 18, 2025, 10:01
May 18, 2025, 09:44
May 18, 2025, 09:43
May 18, 2025, 09:26
May 18, 2025, 09:19
May 18, 2025, 09:17